David J. Pinato

17.5k total citations · 1 hit paper
233 papers, 6.3k citations indexed

About

David J. Pinato is a scholar working on Oncology, Hepatology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, David J. Pinato has authored 233 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 144 papers in Oncology, 105 papers in Hepatology and 50 papers in Pulmonary and Respiratory Medicine. Recurrent topics in David J. Pinato's work include Hepatocellular Carcinoma Treatment and Prognosis (92 papers), Cancer Immunotherapy and Biomarkers (68 papers) and Liver Disease Diagnosis and Treatment (27 papers). David J. Pinato is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (92 papers), Cancer Immunotherapy and Biomarkers (68 papers) and Liver Disease Diagnosis and Treatment (27 papers). David J. Pinato collaborates with scholars based in United Kingdom, Italy and United States. David J. Pinato's co-authors include Rohini Sharma, Francesco Mauri, Mathias Heikenwälder, Bernard V. North, Josep M. Llovet, Richard S. Finn, Eli Pikarsky, Florian Castet, Mala K. Maini and Andrew X. Zhu and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

David J. Pinato

213 papers receiving 6.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Immunotherapies for hepatocellular carcinoma

2021 1.1k citations Mathias Heikenwälder, David J. Pinato et al. profile →

Peers

David J. Pinato

ONCOL

HEPAT

EPIDE

PRM

Ahmed O. Kaseb United States

Li‐Tzong Chen Taiwan

Jean‐Frédéric Blanc France

Adam C. Yopp United States

Tae‐You Kim South Korea

Edwin P. Hui Hong Kong

Koji Umeshita Japan

Yutaka Takeda Japan

Moritz Koch Germany

Mario Scartozzi Italy

Ahmed O. Kaseb United States

David J. Pinato

2.9k ×1.0

ONCOL

3.7k ×1.7

HEPAT

1.8k ×1.3

EPIDE

1.5k ×1.1

1.6k ×1.3

PRM

Citations per year, relative to David J. Pinato David J. Pinato (= 1×) peers Ahmed O. Kaseb

Countries citing papers authored by David J. Pinato

Since Specialization

Citations

This map shows the geographic impact of David J. Pinato's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David J. Pinato with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David J. Pinato more than expected).

Fields of papers citing papers by David J. Pinato

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David J. Pinato. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David J. Pinato. The network helps show where David J. Pinato may publish in the future.

Co-authorship network of co-authors of David J. Pinato

This figure shows the co-authorship network connecting the top 25 collaborators of David J. Pinato. A scholar is included among the top collaborators of David J. Pinato based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David J. Pinato. David J. Pinato is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pinter, Matthias, Claudia Angela Maria Fulgenzi, David J. Pinato, & Bernhard Scheiner. (2025). Systemic treatment in patients with hepatocellular carcinoma and advanced liver dysfunction. Gut. 74(7). 1178–1188. 2 indexed citations

Ibraheim, Hajir, et al.. (2024). The role of the gut microbiome in regulating the response to immune checkpoint inhibitor therapy. Best Practice & Research Clinical Gastroenterology. 72. 101944–101944. 3 indexed citations

Cabibbo, Giuseppe, Ciro Celsa, Marco Enea, et al.. (2024). Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death. Clinical Cancer Research. 31(3). 543–550. 6 indexed citations

Mauro, Ezequiel, Manuel Rodríguez‐Perálvarez, Antonio D’Alessio, et al.. (2024). New Scenarios in Liver Transplantation for Hepatocellular Carcinoma. Liver International. 45(4). e16142–e16142. 5 indexed citations

Jani, Chinmay, Omar Al Omari, Harpreet Singh, et al.. (2023). Geographic and temporal trends in aetiology, incidence and mortality from hepatocellular carcinoma in European Union 15+ countries. 4(3-4). 109–120. 1 indexed citations

Agirrezabal, Ion, Mohamed Bouattour, David J. Pinato, et al.. (2023). Efficacy of transarterial radioembolization using Y-90 resin microspheres versus atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A matching-adjusted indirect comparison. European Journal of Cancer. 196. 113427–113427. 8 indexed citations

Semmler, Georg, Bernhard Scheiner, Lorenz Balcar, et al.. (2023). Disturbances in sodium and chloride homeostasis predict outcome in stable and critically ill patients with cirrhosis. Alimentary Pharmacology & Therapeutics. 58(1). 71–79. 8 indexed citations

Pinato, David J., Xiaoxue Li, Pallavi S. Mishra‐Kalyani, et al.. (2023). Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma. JHEP Reports. 5(6). 100747–100747. 33 indexed citations

Fulgenzi, Claudia Angela Maria, Bernhard Scheiner, Alessandra Gennari, et al.. (2023). Efficacy and safety of frontline systemic therapy for advanced HCC: A network meta-analysis of landmark phase III trials. JHEP Reports. 5(5). 100702–100702. 34 indexed citations

10.

Pinato, David J., Ruth Plummer, Martin Gutierrez, et al.. (2022). 622 A phase 1 study exploring the safety and tolerability of the small-molecule PD-L1 inhibitor, INCB099318, in patients with select advanced solid tumors. Regular and Young Investigator Award Abstracts. A654–A654. 3 indexed citations

11.

Pinter, Matthias, David J. Pinato, Pierluigi Ramadori, & Mathias Heikenwälder. (2022). NASH and Hepatocellular Carcinoma: Immunology and Immunotherapy. Clinical Cancer Research. 29(3). 513–520. 57 indexed citations

12.

Majeed, Ammar, Anouk Dev, Guy D. Eslick, et al.. (2022). Clinical Utility of Albumin Bilirubin Grade as a Prognostic Marker in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: a Systematic Review and Meta-analysis. Journal of Gastrointestinal Cancer. 54(2). 420–432. 14 indexed citations

13.

Cutsem, Eric Van, Hans Prenen, Kristen Spencer, et al.. (2021). 529 Phase 1 study of INCB086550, an oral PD-L1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors. SHILAP Revista de lepidopterología. A559–A560. 11 indexed citations

14.

Howell, Jessica, Stephen R. Atkinson, David J. Pinato, et al.. (2021). Mutations in circulating cell‐free tumour DNA: Predictors of survival in hepatocellular carcinoma. Minerva Access (University of Melbourne). 2(2). 54–62. 1 indexed citations

15.

Allara, Elias, Tadaaki Arizumi, Dominik Bettinger, et al.. (2020). Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study. British Journal of Cancer. 124(2). 407–413. 17 indexed citations

16.

Personeni, Nicola, Ana Lleò, Tiziana Pressiani, et al.. (2020). Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options. Cancers. 12(11). 3370–3370. 32 indexed citations

17.

Teh, Jhia Jiat, et al.. (2019). The systemic inflammatory response as a source of biomarkers and therapeutic targets in hepatocellular carcinoma. Liver International. 39(11). 2008–2023. 58 indexed citations

18.

Trousil, Sebastian, David J. Pinato, James K. Ellis, et al.. (2014). Alterations of Choline Phospholipid Metabolism in Endometrial Cancer Are Caused by Choline Kinase Alpha Overexpression and a Hyperactivated Deacylation Pathway. Cancer Research. 74(23). 6867–6877. 86 indexed citations

19.

Blagden, Sarah P., Debra H. Josephs, Chara Stavraka, et al.. (2014). First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer. Clinical Cancer Research. 20(23). 5908–5917. 36 indexed citations

20.

Pinato, David J., Bernard V. North, & Rohini Sharma. (2012). A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI). British Journal of Cancer. 106(8). 1439–1445. 348 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact